Systemic sclerosis & Raynaud's
Amelioration of Fibrotic Remodeling of Human 3‐Dimensional Full‐Thickness Skin by Transglutamase 2 Inhibition
Authors' conclusion
We provide the first evidence, to our knowledge, that inhibition of TG2 might be a potential antifibrotic approach in SSc.
Study context
- Population
- Skin, dermal fibroblasts and plasma from patients with systemic sclerosis (SSc) and healthy controls
- Comparison
- Monoclonal inhibitory anti-TG2 antibodies in fibroblast cultures and a 3-dimensional full-thickness skin model; SSc vs healthy controls for TG2 expression
Methodological details2-dimensional fibroblast culture, 3-dimensional full-thickness equivalent skin model
- 2-dimensional fibroblast culture
- 3-dimensional full-thickness equivalent skin model
Main finding
As reported in the abstract
- TG2 expression increased in SSc skin vs healthy controls, particularly high in SSc-ILD
- TG2 expression and activity increased in SSc dermal fibroblasts
- Circulating plasma TG2 increased in SSc vs healthy controls
- Anti-TG2 antibodies: no consistent antifibrotic effects across fibroblast cell lines in 2-dimensional culture
- Anti-TG2 antibodies reduced TGFβ-induced dermal thickening, myofibroblast differentiation and collagen accumulation in 3-dimensional full-thickness skin model
Original publication
Amelioration of Fibrotic Remodeling of Human 3‐Dimensional Full‐Thickness Skin by Transglutamase 2 Inhibition. Arthritis Rheumatol. Published 5 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →